Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Liabilities and Shareholders Equity (2020 - 2025)

Maxcyte (MXCT) has disclosed Liabilities and Shareholders Equity for 6 consecutive years, with $213.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 14.13% to $213.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $902.7 million, a 12.05% decrease, with the full-year FY2024 number at $239.5 million, down 10.74% from a year prior.
  • Liabilities and Shareholders Equity was $213.5 million for Q3 2025 at Maxcyte, down from $219.8 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $291.0 million in Q1 2022 to a low of $93.1 million in Q2 2021.
  • A 5-year average of $253.2 million and a median of $267.5 million in 2023 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 448.71% in 2021, then dropped 14.13% in 2025.
  • Maxcyte's Liabilities and Shareholders Equity stood at $284.1 million in 2021, then rose by 0.89% to $286.7 million in 2022, then fell by 6.41% to $268.3 million in 2023, then decreased by 10.74% to $239.5 million in 2024, then dropped by 10.85% to $213.5 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Liabilities and Shareholders Equity are $213.5 million (Q3 2025), $219.8 million (Q2 2025), and $230.0 million (Q1 2025).